CA-ZTE-USA
ZTE USA, the fourth largest smartphone manufacturer in the U.S. and second largest in the off-contract market*, kicked off the New Year early by unveiling its new global brand identity in the U.S. today at a Golden State Warriors home game at Oracle Arena. The more consumer-focused branding includes a new logo and tagline, “Tomorrow never waits,” marking the 30th anniversary of the company and emphasizing its focus on transformative mobile technology solutions for its consumers and carrier partners. While ZTE introduced its new brand identity yesterday at an event in Hong Kong, this was the first time the company brought it to the U.S. as part of its relationship as the official smartphone of the Golden State Warriors.
Under ZTE’s new corporate evolution towards greater emphasis in the mobile internet technology and ecosystem that takes on a more consumer-centric emphasis, the company is committed to driving innovation in telecommunications, enterprise computing and consumer devices to help consumers adapt and thrive in the era of intelligent, always-on connectivity. The new ZTE slogan, “Tomorrow never waits”, reflects the company’s ongoing commitment to providing consumers with access to technology solutions that will define the future.
“As one of ZTE’s most important markets, the U.S., and more specifically the Bay Area, is one of the first places we wanted to introduce our new branding,” said Lixin Cheng, chairman and CEO, ZTE USA. “The community the Warriors serve is one of the most innovative in the world. We see that innovation and the Warriors winning attitude as characteristics that ZTE aspires to achieve in the years ahead.”
In addition to the new brand visual identity, ZTE held a phone donation drive with the Golden State Warriors, a philanthropic effort designed to benefit the Warriors Community Foundation’s Hoops for Kids program, giving Bay Area youth the gift of technology they might not otherwise receive.
“As an organization, we are always striving to be at the forefront of innovation and we are honored ZTE has chosen Oracle Arena and the Warriors community to unveil their new brand identity to for the first time in the United States,” said Chip Bowers, chief marketing officer of the Golden State Warriors. “We are also proud to partner with ZTE on the community phone drive to further help support those in our community who support us night in and night out.”
About ZTE USA
ZTE USA (www.zteusa.com ) is a subsidiary of ZTE Corporation, a leading global provider of mobile handsets, telecommunications equipment and network solutions. Operating since 1998, ZTE USA is dedicated to making cost-efficient, quality communication technology accessible to all. The company provides a magnitude of devices to every major US-based carrier, generates over $17.4 billion dollars’ worth of business for US-based companies and devotes more than 10 percent of its revenue to R&D. ZTE USA is headquartered in Richardson, Texas and operates 17 sales offices, customer service centers, R&D and distribution facilities across the US. ZTE is ranked as the country’s fourth-largest supplier of mobile devices overall, and second-largest supplier of prepaid devices, by independent analysts. ZTE is the Official Smartphone of the Golden State Warriors, Houston Rockets and New York Knicks.
Visit ZTE USA on YouTube https://www.youtube.com/user/ZTEUSAInc , LinkedIn https://www.linkedin.com/company/zteusa , Facebook https://www.facebook.com/ZTEUSA , and Twitter https://twitter.com/ZTE_USA .
*Strategy Analytics, North America Handset Vendor Market Share, Q3 2014
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141231005301/en/
Contact:
Grayling for ZTE USA
Allie Zamaria, +1 323-648-5427
allie.zamaria@grayling.com
or
ZTE
USA
Andrew Elliott, +1 972-375-1532
andrew.elliott@zteusa.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum